Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease
Identifieur interne : 000A82 ( Istex/Corpus ); précédent : 000A81; suivant : 000A83Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease
Auteurs : Rascol ; U. Sabatini ; N. Fabre ; J. M. Senard ; M. Simonetta-Moreau ; J. L. Montastruc ; M. Clanet ; A. RascolSource :
- Movement Disorders [ 0885-3185 ] ; 1995-03.
English descriptors
- KwdEn :
Abstract
We have measured the gain of the vestibuloocular reflex (VOR) in darkness and its cancellation by fixation in 37 patients with Parkinson's disease (PD), 26 patients with multiple system atrophy (MSA), 11 patients with progressive supranuclear palsy (PSP), and 19 normal volunteers. The capacity to cancel the VOR by fixation (VOR cancellation) was significantly reduced in the MSA and PSP patients compared with the PD and normal subjects (p < 10−4). A VOR cancellation < 90% (i.e., the mean VOR cancellation of the normals ‐ 2 SD) was present in four PD patients, 23 MSA patients, and 11 PSP patients. This criteria distinguished PD and MSA with a 89% sensitivity and a 89% specificity. Our results demonstrate that the VOR cancellation is impaired in most patients with MSA and PSP but not with PD. In MSA patients, the abnormal VOR cancellation is probably not related to the nigrostriatal dopaminergic deficit and more likely reflects a cerebellar dysfunction. Impaired VOR cancellation is a clinical criteria to differentiate MSA and PSP from PD.
Url:
DOI: 10.1002/mds.870100206
Links to Exploration step
ISTEX:60C7E4DF9958BAD417EDF66D394BBED809729258Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name><affiliation><mods:affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Otoneurological Unit, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U." last="Sabatini">U. Sabatini</name><affiliation><mods:affiliation>The Neurological Clinic of the University Hospital of Rome‐La Sapienza, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation><mods:affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name><affiliation><mods:affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Simonetta Oreau, M" sort="Simonetta Oreau, M" uniqKey="Simonetta Oreau M" first="M." last="Simonetta-Moreau">M. Simonetta-Moreau</name><affiliation><mods:affiliation>Laboratory of Physiology, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation><mods:affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Clanet, M" sort="Clanet, M" uniqKey="Clanet M" first="M." last="Clanet">M. Clanet</name><affiliation><mods:affiliation>Otoneurological Unit, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation><mods:affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:60C7E4DF9958BAD417EDF66D394BBED809729258</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100206</idno><idno type="url">https://api.istex.fr/document/60C7E4DF9958BAD417EDF66D394BBED809729258/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name><affiliation><mods:affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Otoneurological Unit, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U." last="Sabatini">U. Sabatini</name><affiliation><mods:affiliation>The Neurological Clinic of the University Hospital of Rome‐La Sapienza, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation><mods:affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name><affiliation><mods:affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Simonetta Oreau, M" sort="Simonetta Oreau, M" uniqKey="Simonetta Oreau M" first="M." last="Simonetta-Moreau">M. Simonetta-Moreau</name><affiliation><mods:affiliation>Laboratory of Physiology, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation><mods:affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Clanet, M" sort="Clanet, M" uniqKey="Clanet M" first="M." last="Clanet">M. Clanet</name><affiliation><mods:affiliation>Otoneurological Unit, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation><mods:affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-03">1995-03</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="163">163</biblScope><biblScope unit="page" to="170">170</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">60C7E4DF9958BAD417EDF66D394BBED809729258</idno><idno type="DOI">10.1002/mds.870100206</idno><idno type="ArticleID">MDS870100206</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Multiple system atrophy</term><term>Parkinson's disease</term><term>Supranuclear palsy</term><term>Vestibuloocular reflex cancellation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have measured the gain of the vestibuloocular reflex (VOR) in darkness and its cancellation by fixation in 37 patients with Parkinson's disease (PD), 26 patients with multiple system atrophy (MSA), 11 patients with progressive supranuclear palsy (PSP), and 19 normal volunteers. The capacity to cancel the VOR by fixation (VOR cancellation) was significantly reduced in the MSA and PSP patients compared with the PD and normal subjects (p < 10−4). A VOR cancellation < 90% (i.e., the mean VOR cancellation of the normals ‐ 2 SD) was present in four PD patients, 23 MSA patients, and 11 PSP patients. This criteria distinguished PD and MSA with a 89% sensitivity and a 89% specificity. Our results demonstrate that the VOR cancellation is impaired in most patients with MSA and PSP but not with PD. In MSA patients, the abnormal VOR cancellation is probably not related to the nigrostriatal dopaminergic deficit and more likely reflects a cerebellar dysfunction. Impaired VOR cancellation is a clinical criteria to differentiate MSA and PSP from PD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Rascol</name><affiliations><json:string>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</json:string><json:string>Otoneurological Unit, Toulouse, France</json:string></affiliations></json:item><json:item><name>U. Sabatini</name><affiliations><json:string>The Neurological Clinic of the University Hospital of Rome‐La Sapienza, Rome, Italy</json:string></affiliations></json:item><json:item><name>N. Fabre</name><affiliations><json:string>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>J. M. Senard</name><affiliations><json:string>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</json:string></affiliations></json:item><json:item><name>M. Simonetta‐Moreau</name><affiliations><json:string>Laboratory of Physiology, Toulouse, France</json:string></affiliations></json:item><json:item><name>J. L. Montastruc</name><affiliations><json:string>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</json:string></affiliations></json:item><json:item><name>M. Clanet</name><affiliations><json:string>Otoneurological Unit, Toulouse, France</json:string><json:string>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>A. Rascol</name><affiliations><json:string>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Vestibuloocular reflex cancellation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Supranuclear palsy</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We have measured the gain of the vestibuloocular reflex (VOR) in darkness and its cancellation by fixation in 37 patients with Parkinson's disease (PD), 26 patients with multiple system atrophy (MSA), 11 patients with progressive supranuclear palsy (PSP), and 19 normal volunteers. The capacity to cancel the VOR by fixation (VOR cancellation) was significantly reduced in the MSA and PSP patients compared with the PD and normal subjects (p > 10−4). A VOR cancellation > 90% (i.e., the mean VOR cancellation of the normals ‐ 2 SD) was present in four PD patients, 23 MSA patients, and 11 PSP patients. This criteria distinguished PD and MSA with a 89% sensitivity and a 89% specificity. Our results demonstrate that the VOR cancellation is impaired in most patients with MSA and PSP but not with PD. In MSA patients, the abnormal VOR cancellation is probably not related to the nigrostriatal dopaminergic deficit and more likely reflects a cerebellar dysfunction. Impaired VOR cancellation is a clinical criteria to differentiate MSA and PSP from PD.</abstract><qualityIndicators><score>6.996</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1051</abstractCharCount><pdfWordCount>4944</pdfWordCount><pdfCharCount>30467</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>171</abstractWordCount></qualityIndicators><title>Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>10</volume><pages><total>8</total><last>170</last><first>163</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1002/mds.870100206</json:string></doi><id>60C7E4DF9958BAD417EDF66D394BBED809729258</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/60C7E4DF9958BAD417EDF66D394BBED809729258/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/60C7E4DF9958BAD417EDF66D394BBED809729258/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/60C7E4DF9958BAD417EDF66D394BBED809729258/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1995</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title><author><persName><surname>Rascol</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</p></note><affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</affiliation><affiliation>Otoneurological Unit, Toulouse, France</affiliation></author><author><persName><forename type="first">U.</forename><surname>Sabatini</surname></persName><affiliation>The Neurological Clinic of the University Hospital of Rome‐La Sapienza, Rome, Italy</affiliation></author><author><persName><forename type="first">N.</forename><surname>Fabre</surname></persName><affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">J. M.</forename><surname>Senard</surname></persName><affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</affiliation></author><author><persName><forename type="first">M.</forename><surname>Simonetta‐Moreau</surname></persName><affiliation>Laboratory of Physiology, Toulouse, France</affiliation></author><author><persName><forename type="first">J. L.</forename><surname>Montastruc</surname></persName><affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</affiliation></author><author><persName><forename type="first">M.</forename><surname>Clanet</surname></persName><affiliation>Otoneurological Unit, Toulouse, France</affiliation><affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">A.</forename><surname>Rascol</surname></persName><affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-03"></date><biblScope unit="vol">10</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="163">163</biblScope><biblScope unit="page" to="170">170</biblScope></imprint></monogr><idno type="istex">60C7E4DF9958BAD417EDF66D394BBED809729258</idno><idno type="DOI">10.1002/mds.870100206</idno><idno type="ArticleID">MDS870100206</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We have measured the gain of the vestibuloocular reflex (VOR) in darkness and its cancellation by fixation in 37 patients with Parkinson's disease (PD), 26 patients with multiple system atrophy (MSA), 11 patients with progressive supranuclear palsy (PSP), and 19 normal volunteers. The capacity to cancel the VOR by fixation (VOR cancellation) was significantly reduced in the MSA and PSP patients compared with the PD and normal subjects (p < 10−4). A VOR cancellation < 90% (i.e., the mean VOR cancellation of the normals ‐ 2 SD) was present in four PD patients, 23 MSA patients, and 11 PSP patients. This criteria distinguished PD and MSA with a 89% sensitivity and a 89% specificity. Our results demonstrate that the VOR cancellation is impaired in most patients with MSA and PSP but not with PD. In MSA patients, the abnormal VOR cancellation is probably not related to the nigrostriatal dopaminergic deficit and more likely reflects a cerebellar dysfunction. Impaired VOR cancellation is a clinical criteria to differentiate MSA and PSP from PD.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Vestibuloocular reflex cancellation</term></item><item><term>Parkinson's disease</term></item><item><term>Multiple system atrophy</term></item><item><term>Supranuclear palsy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994-07-26">Registration</change><change when="1995-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/60C7E4DF9958BAD417EDF66D394BBED809729258/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v10:2</doi><numberingGroup><numbering type="journalVolume" number="10">10</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="1995-03">March 1995</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="6" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870100206</doi><idGroup><id type="unit" value="MDS870100206"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1995 Movement Disorder Society</copyright><eventGroup><event type="manuscriptAccepted" date="1994-07-26"></event><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">163</numbering><numbering type="pageLast">170</numbering></numberingGroup><correspondenceTo>Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870100206.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="56"></count></countGroup><titleGroup><title type="main" xml:lang="en">Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title><title type="short" xml:lang="en">VOR CANCELLATION IN PARKINSONIAN SYNDROMES</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>O.</givenNames><familyName>Rascol</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af5"><personName><givenNames>U.</givenNames><familyName>Sabatini</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af4"><personName><givenNames>N.</givenNames><familyName>Fabre</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J. M.</givenNames><familyName>Senard</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>M.</givenNames><familyName>Simonetta‐Moreau</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J. L.</givenNames><familyName>Montastruc</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2 #af4"><personName><givenNames>M.</givenNames><familyName>Clanet</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>A.</givenNames><familyName>Rascol</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Otoneurological Unit, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Laboratory of Physiology, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="IT" type="organization"><unparsedAffiliation>The Neurological Clinic of the University Hospital of Rome‐La Sapienza, Rome, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Vestibuloocular reflex cancellation</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">Multiple system atrophy</keyword><keyword xml:id="kwd4">Supranuclear palsy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We have measured the gain of the vestibuloocular reflex (VOR) in darkness and its cancellation by fixation in 37 patients with Parkinson's disease (PD), 26 patients with multiple system atrophy (MSA), 11 patients with progressive supranuclear palsy (PSP), and 19 normal volunteers. The capacity to cancel the VOR by fixation (VOR cancellation) was significantly reduced in the MSA and PSP patients compared with the PD and normal subjects (<i>p</i> < 10<sup>−4</sup>). A VOR cancellation < 90% (i.e., the mean VOR cancellation of the normals ‐ 2 SD) was present in four PD patients, 23 MSA patients, and 11 PSP patients. This criteria distinguished PD and MSA with a 89% sensitivity and a 89% specificity. Our results demonstrate that the VOR cancellation is impaired in most patients with MSA and PSP but not with PD. In MSA patients, the abnormal VOR cancellation is probably not related to the nigrostriatal dopaminergic deficit and more likely reflects a cerebellar dysfunction. Impaired VOR cancellation is a clinical criteria to differentiate MSA and PSP from PD.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>VOR CANCELLATION IN PARKINSONIAN SYNDROMES</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Rascol</namePart><affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</affiliation><affiliation>Otoneurological Unit, Toulouse, France</affiliation><description>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, 37 allées Jules‐Guesde, 31073 Toulouse Cedex, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U.</namePart><namePart type="family">Sabatini</namePart><affiliation>The Neurological Clinic of the University Hospital of Rome‐La Sapienza, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Fabre</namePart><affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. M.</namePart><namePart type="family">Senard</namePart><affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Simonetta‐Moreau</namePart><affiliation>Laboratory of Physiology, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. L.</namePart><namePart type="family">Montastruc</namePart><affiliation>Laboratory of Medical and Clinical Pharmacology (INSERM U 317), Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Clanet</namePart><affiliation>Otoneurological Unit, Toulouse, France</affiliation><affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Rascol</namePart><affiliation>Neurological Departments of the University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1995-03</dateIssued><dateValid encoding="w3cdtf">1994-07-26</dateValid><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">3</extent><extent unit="references">56</extent></physicalDescription><abstract lang="en">We have measured the gain of the vestibuloocular reflex (VOR) in darkness and its cancellation by fixation in 37 patients with Parkinson's disease (PD), 26 patients with multiple system atrophy (MSA), 11 patients with progressive supranuclear palsy (PSP), and 19 normal volunteers. The capacity to cancel the VOR by fixation (VOR cancellation) was significantly reduced in the MSA and PSP patients compared with the PD and normal subjects (p < 10−4). A VOR cancellation < 90% (i.e., the mean VOR cancellation of the normals ‐ 2 SD) was present in four PD patients, 23 MSA patients, and 11 PSP patients. This criteria distinguished PD and MSA with a 89% sensitivity and a 89% specificity. Our results demonstrate that the VOR cancellation is impaired in most patients with MSA and PSP but not with PD. In MSA patients, the abnormal VOR cancellation is probably not related to the nigrostriatal dopaminergic deficit and more likely reflects a cerebellar dysfunction. Impaired VOR cancellation is a clinical criteria to differentiate MSA and PSP from PD.</abstract><subject lang="en"><genre>Keywords</genre><topic>Vestibuloocular reflex cancellation</topic><topic>Parkinson's disease</topic><topic>Multiple system atrophy</topic><topic>Supranuclear palsy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>163</start><end>170</end><total>8</total></extent></part></relatedItem><identifier type="istex">60C7E4DF9958BAD417EDF66D394BBED809729258</identifier><identifier type="DOI">10.1002/mds.870100206</identifier><identifier type="ArticleID">MDS870100206</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1995 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:60C7E4DF9958BAD417EDF66D394BBED809729258
|texte= Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |